The colorectal cancer immune microenvironment and approach to immunotherapies

Future Oncology

Volumn 13, Issue 18, 2017, Pages 1633-1647

  Koi, Minoru ^a   Carethers, John M ^a,b  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

colorectal cancer; colorectal cancer molecular subtype; DNA mismatch repair; EMAST; immune checkpoint inhibitor; immunotherapy; immunotyping; microsatellite instability; patient outcome; tumor microenvironment

Indexed keywords

ACETYLSALICYLIC ACID; FLUOROURACIL; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; TUMOR VACCINE; BIOLOGICAL MARKER;

ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; CANCER ASSOCIATED FIBROBLAST; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; COLORECTAL CANCER; DISEASE FREE SURVIVAL; FUSOBACTERIUM NUCLEATUM; HUMAN; IMMUNOSURVEILLANCE; MEMORY T LYMPHOCYTE; METASTATIC COLORECTAL CANCER; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; SURVIVAL TIME; TH1 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; COLORECTAL TUMOR; CYTOLOGY; GENETICS; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; MULTIMODALITY CANCER THERAPY; MUTATION; PATHOLOGY; PROGNOSIS;

ANIMALS; BIOMARKERS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM STAGING; PROGNOSIS; TUMOR MICROENVIRONMENT;

EID: 85028533400     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon-2017-0145     Document Type: Review

References (109)

1. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), E359-E386 (2015).
2. Siegel RL, Miller KD, Fedewa SA et al. Colorectal cancer statistics, 2017. CA Cancer J. Clin. 67(3), 177-193 (2017).
3. Pages F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353(25), 2654-2666 (2005).
4. Galon J, Costes A, Sanches-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795), 1960-1964 (2006).
5. Camus M, Tosolini M, Mlecnik B et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res. 69(6), 2685-2693 (2009).
6. Pages F, Kirilovsky A, Melecnik B et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J. Clin. Oncol. 27(35), 5944-5951 (2009).
7. Tosolini M, Kirilovsky A, Mlecnik B et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res. 71(4), 1263-1271 (2011).
8. Mlecnik B, Bindea G, Kirilovsky A et al. The tumor microenvironment and immunoscore are critical determinants of dissemination to distant metastasis. Sci. Transl. Med. 8(327), 327ra26 (2016).
9. Becht E, de Reyniès A, Giraldo NA et al. Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy. Clin. Cancer Res. 22(16), 4057-4066 (2016).
10. Galon J, Pages F, Marincola FM et al. Cancer classification using the immunoscore: A worldwide task force. J. Transl. Med. 10, 205 (2012).
11. Eggermont AMM, Chiarion-Sileni V, Grob J-J et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N. Engl. J. Med. 375(19), 1845-1855 (2016).
12. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
13. Brahmer JR, Tykodi SS, Chow LQM et al. Safety and activity of anti-PDL1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012).
14. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509-2520 (2015).
15. MacCarty WC. Factors which influences longevity in cancer. Ann. Surg. 76, 9-12 (1922).
16. Underwood JCE. Lymphoreticular infiltration in human tumors: prognostic and biological implications: A review. Br. J. Cancer 30, 538-548 (1974).
17. Murray D, Hreno A, Dutton J, Hampson LG. Prognosis in colon cancer A pathologic reassessment. Arch. Surg. 110, 908-913 (1975).
18. Watt AG, House AK. Colonic carcinoma A quantitative assessment of lymphocyte infiltration at periphery of colonic tumors related to prognosis. Cancer 41, 279-282 (1978).
19. Engel P, Boumsell L, Balderas R et al. CD nomenclature 2015: human leukocyte differentiation antigen workshops as a driving force in immunology. J. Immunol. 195, 4555-4563 (2015).
20. Muul LM, Spiess PJ, Director EP, Rosenberg SA. Identification of specific cytolytic immune response against autologous tumor in humans bearing malignant melanoma. J. Immunol. 138, 989-995 (1987).
21. Gallagher P, Vose BM, Moore M, Schofield PF. Role of autologous lymphocyte cytotoxicity in colonic neoplasia. Gut 23, 31-35 (1982).
22. Ebert EC, Brolin RE, Roberts AI. Characterization of activated lymphocytes in colon cancer. Clin. Immunol. Immunopathol. 50(1 Pt 1), 72-81 (1989).
23. Vose BM, Moor M. Suppressor cell activity of lymphocytes infiltrating human lung and breast tumors. Int. J. Cancer 24, 579-585 (1979).
24. Holmes EC. Immunology of tumor infiltrating lymphocytes. Ann. Surg. 201, 158-163 (1985).
25. Jass JR. Lymphocytic infiltration and survival in rectal cancer. J. Clin. Pathol. 39, 585-589 (1986).
26. Ogino S, Nosho K, Irahara N et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin. Cancer Res. 15(20), 6412-6420 (2009).
27. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393(6684), 480-483 (1998).
28. Barry M, Bleackley RC. Cytotoxic T lymphocytes: all roads lead to death. Nat. Rev. Immunol. 2(6), 401-409 (2002).
29. Naito Y, Saito K, Shiiba K et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58, 3491-3494 (1998).
30. Mlecnik B, Tosolini M, Charoentong P et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 138(4), 1429-1440 (2010).
31. Rozek LS, Schmit SL, Greenson JK et al. Tumor-infiltrating lymphocytes, Crohn's-like lymphoid reaction, and survival from colorectal cancer. J. Natl Cancer Inst. 108(8), djw027 (2016).
32. Mlecnik B, Tosolini M, Kirilovsky A et al. Histopathologic based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J. Clin. Oncol. 29, 610-618 (2011).
33. Bindea G, Mlecnik B, Tosolini M et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39(4), 782-795 (2013).
34. Angelova M, Charoentong P, Hackl H et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 16, 64 (2015).
35. Bronte Vincenzo, Brandau Sven, Chen Shu-Hsia et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat. Commun. 7, 12150 (2016).
36. OuYang LY, Wu XJ, Ye SB et al. Tumorinduced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer. J. Transl. Med. 13, 47 (2015).
37. Dalton DK, Noelle RJ. The roles of mast cells in anticancer immunity. Cancer Immunol. Immunother. 61(9), 1511-1520 (2012).
38. Yodavudh S, Tangjitgamol S, Puangsa-art S. Prognostic significance of microvessel density and mast cell density for the survival of Thai patients with primary colorectal cancer. J. Med. Assoc. Thai. 91, 723-732 (2008).
39. Amicarella F, Muraro MG, Hirt C et al. Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer. Gut 66, 692-704 (2015).
40. De Simone M, Arrigoni A, Rossetti G et al. Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumorinfiltrating T regulatory cells. Immunity 45(5), 1135-1147 (2016).
41. Torres S, Bartolomé RA, Mendes M et al. Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer. Clin. Cancer Res. 19(21), 6006-6019 (2013).
42. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
43. Carethers JM, Jung BH. Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology 149, 1177-1190 (2015).
44. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135, 1079-1099 (2008).
45. Carethers JM, Koi M, Tseng-Rogenski S. EMAST is a form of microsatellite instability that is initiated by inflammation and modulates colorectal cancer progression. Genes 6, 185-205 (2015).
46. Koi M, Umar A, Chauhan DP et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-Nnitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res. 54, 4308-4314 (1994).
47. Carethers JM, Hawn MT, Chauhan DP et al. Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N'-nitro-N-nitrosoguanidine. J. Clin. Invest. 98, 199-206 (1996).
48. Carethers JM, Stoffel EM. Lynch syndrome and Lynch syndrome mimics: the growing complex landscape of hereditary colon cancer. World J. Gastroenterol. 21, 9253-9261 (2015).
49. Carethers JM. Microsatellite instability pathway and EMAST in colorectal cancer. Curr. Colorectal Cancer Rep. 13(1), 73-80 (2017).
50. Schwitalle Y, Kloor M, Eiermann S et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 134, 988-997 (2008).
51. Tseng-Rogenski SS, Chung H, Wilk MB, Zhang S, Iwaizumi M, Carethers JM. Oxidative stress induces nuclear-to-cytosol shift of hMSH3, a potential mechanism for EMAST in colorectal cancer cells. PLoS ONE 7(11), e50616 (2012).
52. Tseng-Rogenski SS, Hamaya Y, Choi DY, Carethers JM. Interleukin 6 alters localization of hMSH3, leading to DNA mismatch repair defects in colorectal cancer cells. Gastroenterology 148(3), 579-589 (2015).
53. Campregher C, Schmid G, Ferk F et al. MSH3-deficiency initiates EMAST without oncogenic transformation of human colon epithelial cells. PLoS ONE 7(11), e50541 (2012).
54. Boland CR, Thibodeau SN, Hamilton SR et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58, 5248-5257 (1988).
55. Hamaya Y, Guarinos C, Tseng-Rogenski SS et al. Efficacy of 5-fluorouracil adjuvant therapy for patients with EMAST-positive stage II/III colorectal cancers. PLoS ONE 10, e0127591 (2015).
56. Haugen AC, Goel A, Yamada K et al. Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer. Cancer Res. 68(20), 8465-8472 (2008).
57. Yamada K, Kanazawa S, Koike J et al. Microsatellite instability at tetranucleotide repeats in sporadic colorectal cancer in Japan. Oncol. Rep. 23(2), 551-561 (2010).
58. Lee SY, Chung H, Devaraj B et al. Microsatellite alterations at selected tetranucleotide repeats are associated with morphologies of colorectal neoplasias. Gastroenterology 139(5), 1519-1525 (2010).
59. Lee SY, Miyai K, Han HS et al. Microsatellite instability, EMAST, and morphology associations with T cell infiltration in colorectal neoplasia. Dig. Dis. Sci. 57(1), 72-78 (2012).
60. Garcia M, Choi C, Kim HR et al. Association between recurrent metastasis from stage II and III primary colorectal tumors and moderate microsatellite instability. Gastroenterology 143(1), 48-50 (2012).
61. Devaraj B, Lee A, Cabrera BL et al. Relationship of EMAST and microsatellite instability among patients with rectal cancer. J. Gastrointest. Surg. 14, 1521-1528 (2010).
62. Koi M, Garcia M, Choi C et al. Microsatellite alterations with allelic loss on 9p24.2 signify less aggressive colorectal cancer metastasis. Gastroenterology 150, 944-955 (2016).
63. Guinney J, Dienstmann R, Wang X et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21(11), 1350-1356 (2015).
64. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 23(3), 609-618 (2005).
65. Mlecnik B, Bindea G, Angell HK et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 44(3), 698-711 (2016).
66. Bicknell DC, Rowan A, Bodmer WF. Beta 2-microglobulin gene mutations: A study of established colorectal cell lines and fresh tumors. Proc. Natl Acad. Sci. USA 91(11), 4751-4755 (1994).
67. Kloor M, Michel S, von Knebel Doeberitz M. Immune evasion of microsatellite unstable colorectal cancers. Int. J. Cancer 127(5), 1001-1010 (2010).
68. Kloor M, Becker C, Benner A et al. Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res. 65, 6418-6424 (2005).
69. Giannakis M, Mu XJ, Shukla SA et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 15(4), 857-865 (2016).
70. Brennan CA, Garrett WS. Gut microbiota, inflammation, and colorectal cancer. Annu. Rev. Microbiol. 70, 395-411 (2016).
71. Roy S, Trinchieri G. Microbiota: A key orchestrator of cancer therapy. Nature Rev. Cancer 17, 271-286 (2017).
72. Tahara T, Yamamoto E, Suzuki H et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res. 74(5), 1311-1318 (2014).
73. Nosho K, Sukawa Y, Adachi Y et al. Association of Fusobacteriumnucleatum with immunity and molecular alterations in colorectal cancer. World J. Gastroenterol. 22(2), 557-566 (2016).
74. Mima K, Nishihara R, Qian ZR et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 65, 1973-1980 (2016).
75. Dejea CM, Wick EC, Hechenbleikner EM et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc. Natl Acad. Sci. USA 111(51), 18321-18326 (2014).
76. Mima K, Sukawa Y, Nishihara R et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol. 1(5), 653-661 (2015).
77. Kaplan CW, Ma X, Paranjpe A et al. Fusobacterium nucleatum outer membrane proteins Fap2 and RadD induce cell death in human lymphocytes. Infect. Immun. 78(11), 4773-4778 (2010).
78. Kostic AD, Chun E, Robertson L et al. Fusobacteriumnucleatum potentiates intestinal tumorigenesis and modulates the tumorimmunemicroenvironment. Cell Host Microbe 14, 207-215 (2013).
79. Gur C, Ibrahim Y, Isaacson B et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 42, 344-355 (2015).
80. Purdy AK, Campbell KS. Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol. Ther. 8(23), 13-22 (2009).
81. Calon A, Lonardo E, Berenguer-Llergo A et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 47(4), 320-309 (2015).
82. Giraldo NA, Becht E, Pagès F et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin. Cancer Res. 21(13), 3031-3040 (2015).
83. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499(7456), 43-49 (2013).
84. Kitajima T, Koi M, Gutierrez L et al. Loss of heterozygosity (LOH) at the hypoxia inducible factor 3A (HIF3A) locus and loss of protein expression is acquired in colorectal cancer (CRC) metastasis. Gastroenterology 150(4), S366 (2016).
85. Gradin K, Poellinger L, Yamamoto M. Regulation of hypoxia-inducible gene expression after HIF activation. Exp. Cell. Res. 356, 182-186 (2017).
86. Chia WK, Ali R, Toh HC. Aspirin as adjuvant therapy for colorectal cancer reinterpreting paradigms. Nat. Rev. Clin. Oncol. 9, 561-570 (2012).
87. Frouws MA, van Herk-Sukel MPP, Maas HA et al. The mortality reducing effect of aspirin in colorectal cancer patients: interpreting the evidence. Cancer Treat. Rev. 55, 120-127 (2017).
88. Hamada T, Cao Y, Qian ZR et al. Aspirin use and colorectal cancer survival according to tumor CD274 (programmed cell death 1 ligand 1) expression status. J. Clin. Oncol. doi:10.1200/JCO.2016.70.7547 (2017) (Epub ahead of print).
89. Gray RT, Cantwell MM, Coleman HG et al. Evaluation of PTGS2 expression, PIK3CA mutation, aspirin use and colon cancer survival in a population-based cohort study. Clin. Transl. Gastroenterol. 8(4), e91 (2017).
90. Kwon ED, Foster BA, Hurwitz AA et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc. Natl Acad. Sci. USA 96(26), 15074-15079 (1999).
91. Vermorken JB, Claessen AM, van Tinteren H et al. Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial. Lancet 353, 345-350 (1999).
92. Uyl-de Groot CA, Vermorken JB, Hanna MG et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: A prospective study of medical and economic benefits. Vaccine 23, 2379-2387 (2005).
93. de Weger VA, Turksma AW, Voorham QJ et al. Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer. Clin. Cancer Res. 18(3), 882-889 (2012).
94. Zhen YH, Liu XH, Yang Y et al. Phase I/II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer. Cancer Immunol. Immunother. 64(9), 1083-1093 (2015).
95. Mennonna D, Maccalli C, Romano MC et al. T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes. Gut 66(3), 454-463 (2017).
96. Seow HF, Yip WK, Fifis T. Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. Onco. Targets Ther. 9, 1899-1920 (2016).
97. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369(2), 122-133 (2013).
98. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 236, 219-242 (2010).
99. Chung KY, Gore I, Fong L et al. Phase II study of the anti-cytotoxic T-lymphocyteassociated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J. Clin. Oncol. 28(21), 3485-3490 (2010).
100. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167-3175 (2010)
101. Overman MJ, Kopetz S, McDermott RS et al. Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. J. Clin. Oncol. 34(Suppl.), Abstract 3501 (2016).
102. Bendell JC, Powderly JD, Lieu CH et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC). J. Clin. Oncol. 33 (Suppl.) Abstract 704 (2015).
103. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39(1), 74-88 (2013).
104. Tesniere A, Schlemmer F, Boige V et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29(4), 482-491 (2010).
105. Vincent J, Mignot G, Chalmin F et al. 5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70, 3052-3061 (2010).
106. Kakarla S, Song XT, Gottschalk S. Cancerassociated fibroblasts as targets for immunotherapy. Immunotherapy 4(11), 1129-1138 (2012).
107. Cheng JD, Valianou M, Canutescu AA et al. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol. Cancer Ther. 4(3), 351-360 (2005).
108. Scott AM, Wiseman G, Welt S et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res. 9(5), 1639-1647 (2003).
109. Chen M, Xiang R, Wen Y et al. A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts. Sci. Rep. 5, 14421 (2015).